COCP · Cocrystal Pharma, Inc.
$1.11
-0.04 (-3.06%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$21.96M
Shares
19.26M
Volume · Oct 5
41.3K
Avg daily vol (3M)
55.13K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.11
Open$1.18
Day$1.11–1.18
52W close$0.82–1.57
Avg vol 30d50K
Short int323K · 1.7% float · 6.4d
Short vol29%
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$9.94M
Trailing 12 months
Revenue growth YoY
-69.3%
Year over year
Operating margin
-476.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.5%
Year over year · more shares
Price change (1Y)
-6.1%
Trailing year
Short interest
1.7%
Latest settlement · 6.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
+0%
above
RSI (14)
45
neutral
MACD trend
Negative
52-week position
39%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−27%
trailing
YTD return
+13%
this year
Relative strength
−39%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +7 funds added
Insider flow
Accumulating
Net +$80.4K over 90 days · 0% sells
Short interest
Rising
1.68% of float · ▲ +0.1% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
Gross margin
57%
EPS growth
+55%
Y/Y
Free cash flow
$-8.2M
Balance sheet
$40.7M
net debt
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
39%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +7 funds added
Insider flow
Accumulating
Net +$80.4K over 90 days · 0% sells
Short interest
Rising
1.68% of float · ▲ +0.1% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 39%
Range high $2
vs 200-day avg +1%
vs 50-day avg +0%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COCP
this stock
Cocrystal Pharma, Inc.
|
$21.96M | +13.3% | -69.3% | — | 1.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COCP | -8.3% | -1.8% | -27.5% | -3.5% | +13.3% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -9.5% | -2.4% | -39.0% | -5.1% | -0.4% |